Thao H. Nguyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thao H. Nguyen has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Arlene H. Sharpe
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA
24 shared publications - Alison E. Ringel
Ragon Institute of Mass General Brigham, MIT and Harvard, Cambridge, MA, USA
19 shared publications - Amy Y. Huang
Dana-Farber Cancer Institute, Boston, MA, USA
19 shared publications - Brian C. Miller
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
19 shared publications - Gordon J. Freeman
Department of Medical Oncology, Dana-Farber Cancer Institute
19 shared publications - Jared H. Rowe
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
19 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 12 August 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (9) , 1476-1487
A STUB1–CHIC2 complex inhibits CD8+ T cells to restrain tumor immunity
In vivo CRISPR screens in CD8+ T cells have previously uncovered targets for cancer immunotherapy; however, a minority of the genome has been individually annotated, suggesting that additional regulators remain to be discovered. Here we assessed 899 genes in CD8+ T cells responding to murine melanoma and identified the E3 ubiquitin ligase STUB1 as a new negative regulator of anti-tumor CD8+ T cell function. We demonstrated that Stub1 knockout CD8+ T cells effectively control tumor growth across multiple murine models. Mechanistically, STUB1 interacts with the adapter protein CHIC2 to regulate cytokine receptor expression in mouse and human CD8+ T cells. Among the regulated cytokine receptors, interleukin-27 receptor α is essential for tumor growth control mediated by Stub1/Chic2 knockout CD8+ T cells. Together, these findings establish the STUB1-CHIC2 complex as a regulator of cytokine receptor expression in CD8+ T cells and provide rationale for inhibiting this pathway to enhance CD8+ T cell-mediated anti-tumor immunity.
- 12 August 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (9) , 1476-1487
A STUB1–CHIC2 complex inhibits CD8+ T cells to restrain tumor immunity
In vivo CRISPR screens in CD8+ T cells have previously uncovered targets for cancer immunotherapy; however, a minority of the genome has been individually annotated, suggesting that additional regulators remain to be discovered. Here we assessed 899 genes in CD8+ T cells responding to murine melanoma and identified the E3 ubiquitin ligase STUB1 as a new negative regulator of anti-tumor CD8+ T cell function. We demonstrated that Stub1 knockout CD8+ T cells effectively control tumor growth across multiple murine models. Mechanistically, STUB1 interacts with the adapter protein CHIC2 to regulate cytokine receptor expression in mouse and human CD8+ T cells. Among the regulated cytokine receptors, interleukin-27 receptor α is essential for tumor growth control mediated by Stub1/Chic2 knockout CD8+ T cells. Together, these findings establish the STUB1-CHIC2 complex as a regulator of cytokine receptor expression in CD8+ T cells and provide rationale for inhibiting this pathway to enhance CD8+ T cell-mediated anti-tumor immunity.
- 24 July 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (10)
PD-1 regulates tumor-infiltrating CD8+ T cells in both a cell-intrinsic and a cell-extrinsic fashion
Although PD-1 inhibitors are FDA-approved for over 25 different cancers, the mechanisms contributing to response remain incompletely understood. To investigate how PD-1–deleted CD8+ T cells influence PD-1–expressing CD8+ T cells in the same tumor microenvironment, we developed an inducible PD-1 knockout (KO) model in which PD-1 is deleted on ∼50% of cells. PD-1 deletion beginning at day 7 after implantation of MC38 tumor cells led to robust tumor control. Remarkably, PD-1–expressing CD8+ T cells in the tumor had increased functionality similar to PD-1 KO CD8+ T cells. Using single-cell RNA-seq and TCR-seq, we found that the major transcriptional changes following PD-1 deletion were shared by PD-1 KO and PD-1–expressing CD8+ T cells, although PD-1 KO clones preferentially expanded. These data suggest PD-1 inhibitors not only exert cell-intrinsic effects but also may promote increased T cell function through non–cell-autonomous mechanisms, which has important implications for design of PD-1–based cancer immunotherapies.
- 24 July 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (10)
PD-1 regulates tumor-infiltrating CD8+ T cells in both a cell-intrinsic and a cell-extrinsic fashion
Although PD-1 inhibitors are FDA-approved for over 25 different cancers, the mechanisms contributing to response remain incompletely understood. To investigate how PD-1–deleted CD8+ T cells influence PD-1–expressing CD8+ T cells in the same tumor microenvironment, we developed an inducible PD-1 knockout (KO) model in which PD-1 is deleted on ∼50% of cells. PD-1 deletion beginning at day 7 after implantation of MC38 tumor cells led to robust tumor control. Remarkably, PD-1–expressing CD8+ T cells in the tumor had increased functionality similar to PD-1 KO CD8+ T cells. Using single-cell RNA-seq and TCR-seq, we found that the major transcriptional changes following PD-1 deletion were shared by PD-1 KO and PD-1–expressing CD8+ T cells, although PD-1 KO clones preferentially expanded. These data suggest PD-1 inhibitors not only exert cell-intrinsic effects but also may promote increased T cell function through non–cell-autonomous mechanisms, which has important implications for design of PD-1–based cancer immunotherapies.